Antibody drug conjugates

Abstract

The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

1 - 35 . (canceled) 
     
     
         36 . An antibody or antigen binding fragment thereof that specifically bind to human FGFR2 and comprises:
 a heavy chain variable region that comprises: (a) a VH CDR1 of SEQ ID NO: 21, (b) a VH CDR2 of SEQ ID NO: 22, (c) a VH CDR3 of SEQ ID NO: 23; and a light chain variable region that comprises: (d) a VL CDR1 of SEQ ID NO: 31, (e) a VL CDR2 of SEQ ID NO: 32, (f) a VL CDR3 of SEQ ID NO: 33, or   a heavy chain variable region that comprises: (a) a VH CDR1 of SEQ ID NO: 1, (b) a VH CDR2 of SEQ ID NO: 2, (c) a VH CDR3 of SEQ ID NO: 3; and a light chain variable region that comprises: (d) a VL CDR1 of SEQ ID NO: 11, (e) a VL CDR2 of SEQ ID NO: 12, (f) a VL CDR3 of SEQ ID NO: 13,   wherein the CDR is defined in accordance with the Kabat definition.   
     
     
         37 . (canceled) 
     
     
         38 . An antibody or antigen binding fragment which cross competes with the antibody or antigen binding fragment of  claim 36  for binding to human FGFR2. 
     
     
         39 . The antibody or antigen binding fragment of  claim 36 , wherein said antibody is a human antibody. 
     
     
         40 . The antibody or antigen binding fragment of  claim 39 , wherein said antibody is a monoclonal antibody. 
     
     
         41 . The antibody or antigen binding fragment of  claim 36 , wherein said antibody or antigen binding fragment is a single chain antibody (scFv). 
     
     
         42 . A nucleic acid that encodes the antibody or antigen binding fragment of  claim 36 . 
     
     
         43 . A vector comprising the nucleic acid of  claim 42 . 
     
     
         44 . A host cell comprising the vector according to  claim 43 . 
     
     
         45 . A process for producing an antibody or antigen binding fragment comprising cultivating the host cell of  claim 44  and recovering the antibody from the culture. 
     
     
         46 - 47 . (canceled) 
     
     
         48 . A diagnostic reagent comprising the antibody or antigen binding fragment thereof of  claim 36  which is labeled. 
     
     
         49 . The diagnostic reagent of  claim 48 , wherein the label is selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent, and a metal ion.